The makers of branded pharmaceuticals have devised numerous ways to extend patent exclusivity for lucrative products in the United States. In June, the Supreme Court gave the Federal Trade Commission (FTC) clear authority to investigate and prosecute
Read More...
Read the complete post at http://healthaffairs.org/blog/2013/12/04/why-are-cancer-drugs-commonly-the-target-of-schemes-to-extend-patent-exclusivity/?utm_source=rss&utm_medium=rss&utm_campaign=why-are-cancer-drugs-commonly-the-target-of-schemes-to-extend-patent-exclusivity
Posted
Dec 04 2013, 12:47 PM
by
Health Affairs Blog
Filed under: All Categories, Consumers, Policy, Insurance, Payment, Health Care Costs, Spending, Medicare, Competition, Pharma, Business of Health Care